HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.

Biotechnology

Health Care

Life Sciences

Therapeutics

HI-Bio

Travis Murdoch, MD

Lorna Dean

Melisa Martin

Matthew Albert, MD, PhD

Joyce Liaw

Houston Gilbert

Gijsbert Grotenbreg

Donna Flesher

David Schisla

The Leadership Team at HI-Bio is responsible for steering the company towards its strategic goals by overseeing various critical functions. This includes driving scientific research and development, managing operations and finances, ensuring regulatory compliance, and advancing clinical programs. Their collective expertise in biology, medicine, and business management ensures that HI-Bio remains at the forefront of developing precision medicine therapies for immune-mediated diseases.

Leadership Team

Research & Development

Development and Clinical Operations

Leadership Team

About

Team members

Other teams at HI-Bio

Research & Development

Development and Clinical Operations